Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements

Next Previous
Trial Profile

Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevantolol (Primary)
  • Indications Huntington's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors SOM Biotech

    • Most Recent Events

    • 09 Dec 2022 Results assessing the efficacy and safety of SOM3355 with recently identified VMAT2 inhibitory properties, as a repositioned treatment to reduce chorea in Huntington's disease, published in the British Journal of Clinical Pharmacology.
    • 05 Oct 2021 Results presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
    • 04 Oct 2021 According to a SOM Biotech media release, data from this study will be presented at the 34th ECNP Congress, 2021 in Lisbon, Portugal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top